Polakit Teekakirikul.

Daniel S. Herman, Ph.D generic pills ., Lien Lam, Ph.D., Matthew R.G. Taylor, M.D., Ph.D., Libin Wang, M.D., Ph.D., Polakit Teekakirikul, M.D., Danos Christodoulou, B.S., Lauren Conner, B.S., Steven R. DePalma, Ph.D., Barbara McDonough, R.N., Elizabeth Sparks, R.N.P., Debbie Lin Teodorescu, M.A., Allison L. Cirino, C.G.C., Nicholas R. Banner, F.R.C.P., Dudley J. Pennell, M.D., Sharon Graw, Ph.D., Marco Merlo, M.D., Andrea Di Lenarda, M.D., Gianfranco Sinagra, M.D., J. Martijn Bos, M.D., Ph.D., Michael J. Ackerman, M.D., Ph.D., Richard N.

For variables not normally distributed, medians and interquartile ranges are reported. Intravascular ultrasonographic efficacy end factors are reported as medians, with distribution-free 95 percent self-confidence intervals, and treatment groupings were compared with the usage of evaluation of covariance on rank-transformed data after adjustment for baseline values and geographic region. For the transformation in the principal efficacy end point, PAV, a sample of 450 sufferers in each treatment group was required for 90 percent power at a two-sided alpha level of 0.05 to identify a nominal treatment difference of 0.65 percent, assuming a standard deviation of 3.0 percent.